HROWM | Harrow Health, Inc. 11.875% Senior Notes due 2027 Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	26.75 - 26.80
52 Week Range	25.30 - 27.72
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	227
Average Volume	2,347
Shares Outstanding	40,114,821
Market Cap	1,073,071,462
Sector	Healthcare
Industry	Medical - Pharmaceuticals
IPO Date	2022-12-29

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	11.29%
Dividend Per Share	3.02
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	217
Country	USA
Website	HROWM

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

HROWM's peers: HROWL, BWSN, RWAYZ, RWAYL, SCCG

*Chart delayed

Analyzing fundamentals for HROWM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see HROWM Fundamentals page.

Watching at HROWM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on HROWM Technicals page.